Zerbaxa
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Ceftolozane;tazobactam
- Made by
- Merck Sharp & Dohme B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Zerbaxa is indicated for the treatment of the following infections in adults: Complicated intra abdominal infections; Acute pyelonephritis; Complicated urinary tract infections; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Merck Sharp & Dohme B.V. |
|---|---|
| Active substance | Ceftolozane;tazobactam |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J01DI54 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2015-09-18 |
| Last updated by the regulator | 2025-06-12 |
| EMA product number | EMEA/H/C/003772 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).